MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

MC

501.4

+2.82%↑

SANES

8.074

-0.76%↓

SAF

287.1

-0.59%↓

BBVA

15.525

-2.02%↓

BNP

76.46

-0.31%↓

Search

AB Science SA

Uždarymo kaina

1.208 2.03

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

1.18

Max

1.22

Pagrindiniai rodikliai

By Trading Economics

Pajamos

-3.4M

Pardavimai

512K

Pelno marža

-656.641

Darbuotojai

28

EBITDA

-1.9M

Dividendai

By Dow Jones

Kitas uždarbis

2025-09-29

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

81M

Ankstesnė atidarymo kaina

-0.82

Ankstesnė uždarymo kaina

1.208

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

AB Science SA Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-27 22:51; UTC

Uždarbis

Wesfarmers Plans Special Payout to Shareholders as Annual Net Profit Rises 14%

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Rev $4.01B

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H Adj EPS $1.84

2025-08-27 23:57; UTC

Uždarbis

Trip.com Group 1H EPS $1.82

2025-08-27 23:50; UTC

Rinkos pokalbiai

Nikkei May Decline Amid Caution Over Tariff Impact, Chip Demand -- Market Talk

2025-08-27 23:39; UTC

Uždarbis

Correction to Nvidia Earnings Article -- WSJ

2025-08-27 22:59; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2025-08-27 22:59; UTC

Rinkos pokalbiai

HP CEO Sees Strong Back-to-School Spending on PCs -- Market Talk

2025-08-27 22:58; UTC

Uždarbis

South32 Records Significant Items of $71 Million Tied to Worsley, Mozal

2025-08-27 22:57; UTC

Uždarbis

South32 FY Free Cash Flow $192 Million

2025-08-27 22:56; UTC

Uždarbis

South32 FY Total Capital Expenditure $1.35 Billion

2025-08-27 22:56; UTC

Uždarbis

South32 FY Capital Expenditure $963 Million, Excluding EAIs

2025-08-27 22:55; UTC

Uždarbis

South32 Net Cash $123 Million at June 30

2025-08-27 22:54; UTC

Uždarbis

South32: Focused on Maintaining Strong Operating Momentum

2025-08-27 22:53; UTC

Uždarbis

South32: $144 Million Remains to be Returned to Shareholders Under Program

2025-08-27 22:53; UTC

Uždarbis

South32 Extends Capital Management Program for 12 Months

2025-08-27 22:52; UTC

Uždarbis

South32 FY Underlying Ebitda $1.93 Billion, Up 7% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Revenue $5.78 Billion, Up 17% On-Year

2025-08-27 22:51; UTC

Uždarbis

South32 FY Underlying Earnings $666 Million, Up 75% On-Year

2025-08-27 22:50; UTC

Uždarbis

South32 to Pay Final Dividend of 2.6 U.S. Cents/Share

2025-08-27 22:50; UTC

Uždarbis

South32 FY Net Profit $213 Million Vs $203 Million Loss Year Earlier

2025-08-27 22:45; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Capital Expenditure of $148 Million

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Unit Cost of $44/Ton of Ore Processed

2025-08-27 22:44; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Capital Expenditure of $82 Million

2025-08-27 22:43; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Unit Cost of $86/Ton of Ore Processed

2025-08-27 22:43; UTC

Uždarbis

Nvidia Breaks Sales Record Despite Chinese Trade Hiccups -- 5th Update

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Motheo Copper Eq Output to Rise 3% to 61,000 Tons

2025-08-27 22:42; UTC

Uždarbis

Sandfire Resources Expects FY26 Matsa Copper Eq Output to Rise 2% to 96,000 Tons

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources Net Debt $123 Million at June 30

2025-08-27 22:40; UTC

Uždarbis

Sandfire Resources FY Underlying Ebitda $527.7 Million

Akcijų palyginimas

Kainos pokytis

AB Science SA Prognozė

Techninis įvertinimas

By Trading Central

1.426 / 1.448Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Bearish Evidence

Vidutinės trukmės periodas

Bullish Evidence

Ilgalaikis periodas

Bullish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę AB Science SA

AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.